Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Aytu Biopharma (AYTU) over the last 13 years, with Sep 2025 value amounting to $36.7 million.

  • Aytu Biopharma's Accumulated Expenses rose 8.83% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 8.83%. This contributed to the annual value of $38.2 million for FY2025, which is 0.06% up from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Accumulated Expenses is $36.7 million, which was down 3.84% from $38.2 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Accumulated Expenses peaked at $57.2 million during Q2 2021, and registered a low of $33.7 million during Q3 2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $40.7 million (2023), whereas its average is $41.1 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first spiked by 548.10% in 2021, then fell by 23.81% in 2022.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Accumulated Expenses stood at $50.7 million in 2021, then fell by 18.68% to $41.2 million in 2022, then climbed by 5.33% to $43.4 million in 2023, then dropped by 9.31% to $39.4 million in 2024, then climbed by 8.83% to $36.7 million in 2025.
  • Its Accumulated Expenses was $36.7 million in Q3 2025, compared to $38.2 million in Q2 2025 and $41.7 million in Q1 2025.